UPA looks to end deadlock over FDI, to meet to discuss provision of voting

November 27, 2012

manmohan_manmohan_2611

New Delhi, November 27: The deadlock in Parliament over FDI in multi-brand retail continues. After Monday's inconclusive all-party meet, the UPA coordination committee will meet on Tuesday to discuss the provision of voting. Prime Minister Manmohan Singh, too, will meet Congress allies on the issue.

Sources say the government is against having a vote, but if forced to do so, it is sure of the support of the Samajwadi Party and the Bahujan Samaj Party. Sources say the DMK is against FDI in retail but doesn't want voting, while other allies like the RLD, NCP and the National Conference are with the government for a discussion without vote.

However, sources say that the government is worried that if it sticks to it's stand of no vote, the deadlock in Parliament will continue. This is not something the government wants because it needs to pass important bills like insurance, banking and Lokpal to get over its policy paralysis and keep reforms on track. Sources say the government will convey its decision to the Speaker and the Opposition soon.

Meanwhile, in a major relief for the embattled Congress-led UPA, the Trinamool Congress, Bahujan Samaj Party and Samajwadi Party have decided against opposing the Central Government's proposal for discussion without voting on FDI in retail in Parliament. The government's trouble shooters at the all-party meet managed to convince most of the parties to go for only discussion on FDI and let Parliament function, effectively ending the debate over the numbers backing the government in Parliament, particularly the Lok Sabha where the UPA is now in minority.

Apart from the BJP, JD(U), Left Front and AIADMK, all the other parties who wanted a debate only if it entailed voting have agreed to the government's proposal for a discussion on FDI which was seen as Parliamentary Affairs Minister Kamal Nath's first major challenge. "We have had useful discussion. All parties say House must run. I have appealed to those who wanted discussion under Rule 184 to reconsider their decision. I will speak to the presiding officers," said Nath.

The support of the Bahujan Samaj Party (BSP) has come on one condition. They want the government to bring the quota bill before the FDI. Mayawati has asked for a commitment from the government on the passage of the bill that provides for SC/ST reservation in promotion in government jobs.

"The SC/ST quota bill has been pending for long time. We have been raising this issue for a long time inside as well as outside Parliament. BSP wants Parliament to function and FDI should be discussed. The rule under which discussion on FDI takes place should be decided by the Speaker in the Lok Sabha and the Chairperson in the Rajya Sabha," Mayawati said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 15,2020

New Delhi, May 15: With an increase of 3,967 COVID-19 cases in the last 24 hours, India's tally of coronavirus cases reached 81,970 cases, according to the Union Ministry of Health and Family Welfare on Friday.

According to the latest figures, 51,401 patients are active coronavirus cases while 27,919 patients have been cured/discharged and one patient has been migrated.

With a rise in 100 deaths due to COVID-19 in the last 24 hours, the number of deaths now stands at 2,649.

According to the Health Ministry, Maharashtra is the worst-hit state with regard to the number of COVID-19 cases with 27,524 cases of which, 6,059 patients have been cured/discharged and 1,019 succumbing to the virus.

Tamil Nadu has a tally of 9,674 cases inclusive of 2,240 patients cured/discharged and 66 fatalities.

Gujarat has a total of 9,591 cases which include 3,753 patients cured/discharged while 586 have lost their lives due to coronavirus.

Delhi has a tally of 8,470 cases of which 3,045 patients cured/discharged and 115 fatalities.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Bloomberg
July 27,2020

New Delhi, Jul 27: India’s coronavirus epidemic is now growing at the fastest in the world, increasing 20% over the last week to more than 14 lakh confirmed cases, according to Bloomberg’s Coronavirus Tracker.

Infections in the South Asian nation of 130 crore people have reached 14.3 lakh, including 32,771 deaths, India’s health ministry said, with daily cases close to a record 50,000 on Monday. India is only trailing the US and Brazil now in the number of confirmed infections, but its growth in new cases is the fastest.

Maharashtra, Tamil Nadu, Andhra Pradesh and Karnataka are among the states where the maximum number of daily cares are being reported. The world’s second-most populous country has been ramping up testing, with 515,472 samples taken on Sunday, according to the Indian Council of Medical Research.

Still, India and Brazil have some of the world’s lowest testing rates, with 11.8 tests and 11.93 tests per 1,000 people respectively, compared to the US with 152.98 tests per 1,000 and Russia with 184.34, according to Our World in Data, a project based at the University of Oxford in the UK.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
June 25,2020

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.